About Nicole
Nicole Ballew Chang is a patent agent in the Intellectual Property & Technology Practice, with a focus on biotechnology, life sciences and chemical arts.
Nicole has experience in molecular and cellular biology, which provides her with distinctive insight into intellectual property challenges for her clients within the scientific industry, including patent drafting, prosecution, and due diligence analysis.
Nicole has extensive experience working directly with researchers at companies to draft and prosecute applications in technologies including coronavirus and cancer vaccines, antibodies, cancer immunotherapies, nutraceuticals and biological bone implants.
Credentials
Education
- Dartmouth Medical School, Ph.D., 2003
- Claremont McKenna College, B.A., Cum Laude, 1994
Courts
- U.S. Patent and Trademark Office, 2007
Expertise
Services
- Intellectual Property & Technology
Industries
- Life Sciences
Publications
- Co-author, “Optimization of Humanized IgGs in Glycoengineered Pichia pastoris,” Nature Biotechnol, January 2006.
- Co-author, “A Rab Requirement is Not Bypassed in SLY1-20 Suppression,” Molecular Biology of the Cell, April 2005.
- Co-author, “Production of therapeutic proteins in fungal hosts,” Expert Opinion of Biological Therapy, May 2004.
- Author, “Affinium Pharmaceuticals, Inc: Structure-Guided Drug Discovery,” Chemistry & Biology, May 2004.
- Author, “Benitec, Ltd. Gene Silencing from Down Under,” Chemistry & Biology, March 2004.
- Author, “Tools for Nanoscience at McGill University, Sometimes Smaller is Better,” Chemistry & Biology, January 2004.
- Author, “Cortex Pharmaceuticals, Inc., Maintaining Brain Function Goes a Long Way,” Chemistry & Biology, November 2003.
- Author, “ImmunoGen, Inc., Immunoconjugates in Cancer Therapy: If At First You Don’t Succeed, Try, Try Again,” Chemistry & Biology, September 2003.
- Author, “Tethering of COPII Vesicles to the Golgi Complex in Saccharomyces cerevisiae,” Doctoral Thesis, Dartmouth College, June 23, 2003.
- Author, “Neurocrine Biosciences, Inc., Soporific Science,” Chemistry & Biology, May 2003.
- Co-author, “Initial docking of ER-derived vesicles requires Uso1p and Ypt1p but is independent of SNARE proteins,” EMBO J., April 1998.
About our firm
One of the world’s strongest integrated law firms, providing insight at the point where law, business and government meet. We deliver commercially focused business solutions by combining our legal, lobbying and political capabilities and invaluable connections on the ground to a diverse mix of clients, from long-established leading corporations to emerging businesses, startup visionaries and sovereign nations. More than 1,500 lawyers in over 40 offices across four continents provide unrivaled access to expertise.